Background: Catatonia is a severe motor syndrome found in approximately 10% of all acute psychiatric hospital admissions. It can occur in various psychiatric diseases. The authors report the first case report of catatonia during cannabis withdrawal.
Case Presentation: Mr. A, a 32-year-old man, reported to have smoked approximately 20 g of cannabis daily since the age of 11. Mr. A was incarcerated and was reported 3 weeks later to the medical department for having completely ceased talking and eating. At admission in the authors' department, the patient presented with classical catatonia symptoms (Bush-Francis Catatonia Rating Scale [BFCRS] score = 39/69). All laboratory results and brain magnetic resonance imaging (MRI) were normal. Six weeks after his admission and treatments by lorazepam and memantine, his BFCRS score was 0/69.
Discussion: This single case study highlights the previously underreported emergence of physical and motor symptoms following cannabis withdrawal. Pathophysiological aspects of abrupt cannabis cessation contributing to γ-aminobutyric acid (GABA)/glutamate balance dysregulation and to catatonia are discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/08897077.2015.1052869 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Use of Zolpidem in Catatonia: A Case Report.
Cureus
November 2024
Old Age Psychiatry, University Hospital Wishaw, Wishaw, GBR.
Catatonia is a complex neuropsychiatric syndrome characterised by abnormal psychomotor disturbance, which poses a diagnostic and treatment challenge to clinicians. It is a life-threatening condition in its severe form, termed malignant and characterised by hyperthermia and autonomic disturbances. Early recognition and treatment are important in its management.
View Article and Find Full Text PDFA Case Report of Psilocybin-induced Psychosis in a Predisposed Patient.
Clin Psychopharmacol Neurosci
November 2024
Mental Health Service, San Francisco VA Health Care System, San Francisco, CA, USA.
Psilocybin is gaining popularity as research shows potential benefits to those with anxiety, depression, and other mental health conditions. Individuals with risk factors for psychosis are typically excluded from such studies, limiting the empiric research of the risks and benefits in vulnerable populations. In the real-world setting, many individuals who seek treatment with psilocybin will have comorbid psychiatric conditions and other factors that predispose them to psychosis.
View Article and Find Full Text PDFCatatonia Induced by First-Time Use of Synthetic Cannabinoids: A Case Report.
Cureus
January 2024
Psychiatry, St. Luke's Health Network, Lehighton, USA.
We present the case of a 32-year-old woman who developed life-threatening catatonia in the setting of synthetic cannabis use. She was treated with high doses of lorazepam (up to 26 mg) and eventually transferred to receive electroconvulsive therapy (ECT). Synthetic cannabis poses a unique risk as it is widely available, difficult to regulate, and with adverse effects that are not well understood due to the presence of ever-changing chemical compounds.
View Article and Find Full Text PDFRecurrent cannabis-induced catatonia: a case report and comprehensive systematic literature review.
Front Psychiatry
January 2024
Substance Abuse Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Background: Catatonia presents itself as a complex neuropsychiatric syndrome, giving rise to various motor, speech, and behavioral challenges. It is noteworthy that approximately 10% of psychiatric hospital admissions can be attributed to this condition. It is imperative to note that cannabis-induced catatonia, while infrequent, has been linked to the use of marijuana.
View Article and Find Full Text PDFA Case of Cannabis-Induced Catatonia and Management With Electroconvulsive Therapy.
Cureus
August 2023
Psychiatry, The Wright Center for Graduate Medical Education, Scranton, USA.
This is a case of cannabis-induced catatonia in an 18-year-old Hispanic male with no prior psychiatric history. Shortly after consuming marijuana, the patient experienced catatonic symptoms and demonstrated resistance to several medicinal therapies. Electroconvulsive therapy (ECT) proved to be a useful treatment choice, resulting in significant improvement in symptoms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!